Pure Global AI
NCT06156215Not yet recruiting

PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED

University of California, San FranciscoClinicalTrials.govbehavioral
Verified
Study focus
Disease/Condition
COVID-19
Drug/Device/Intervention
Vaccine Messaging
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
University of California, San Francisco
Location
San Francisco,San Francisco,Durham,Philadelphia,Philadelphia,Philadelphia,Houston, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2024
End date
Jul 31, 2024
Enrollment
744 participants
Primary outcome

30-day booster vaccine uptake

Summary

The goal of this cluster randomized clinical trial is to test the efficacy of messaging
 interventions to increase booster vaccine uptake in adults in the emergency department(ED).
 The main question[s] it aims to answer are:
 
 - does vaccine messaging increase booster vaccine uptake at 30 days post ED visit
 
 - does asking about vaccine acceptance increase booster vaccine uptake at 30 days post ED
 visit
 
 All participants will answer two surveys about booster vaccines and intervention participants
 will receive messaging about booster vaccines.Intervention participants will receive either a
 question about booster vaccine acceptance, or both a question about acceptance and messaging
 about booster vaccines.
 
 If there is a comparison group: Researchers will compare groups to see if vaccine messaging,
 or questions about vaccination affects uptake.

ICD-10 classifications
COVID-19, virus identifiedCOVID-19, virus not identifiedCoronavirus infection, unspecified siteViral infection, unspecifiedRift Valley fever
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06156215
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06156215 through Pure Global AI's free database. This phase not specified trial is sponsored by University of California, San Francisco and is currently Not yet recruiting. The study focuses on COVID-19. Target enrollment is 744 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.